Literature DB >> 31375600

Adeno-associated virus in the liver: natural history and consequences in tumour development.

Tiziana La Bella1,2, Sandrine Imbeaud1,2, Camille Peneau1,2, Iadh Mami1,2, Shalini Datta1,2,3, Quentin Bayard1,2, Stefano Caruso1,2, Theo Z Hirsch1,2, Julien Calderaro1,2,4, Guillaume Morcrette1,2,5,6, Catherine Guettier5,6, Valerie Paradis2,7,8, Giuliana Amaddeo9,10, Alexis Laurent11, Laurent Possenti12, Laurence Chiche13, Paulette Bioulac-Sage14,15, Jean-Frederic Blanc12,14,15, Eric Letouze1,2, Jean-Charles Nault1,2,16, Jessica Zucman-Rossi1,2,17.   

Abstract

OBJECTIVE: Adeno-associated virus (AAV) is a defective mono-stranded DNA virus, endemic in human population (35%-80%). Recurrent clonal AAV2 insertions are associated with the pathogenesis of rare human hepatocellular carcinoma (HCC) developed on normal liver. This study aimed to characterise the natural history of AAV infection in the liver and its consequence in tumour development.
DESIGN: Viral DNA was quantified in tumour and non-tumour liver tissues of 1461 patients. Presence of episomal form and viral mRNA expression were analysed using a DNAse/TaqMan-based assay and quantitative RT-PCR. In silico analyses using viral capture data explored viral variants and new clonal insertions.
RESULTS: AAV DNA was detected in 21% of the patients, including 8% of the tumour tissues, equally distributed in two major viral subtypes: one similar to AAV2, the other hybrid between AAV2 and AAV13 sequences. Episomal viral forms were found in 4% of the non-tumour tissues, frequently associated with viral RNA expression and human herpesvirus type 6, the candidate natural AAV helper virus. In 30 HCC, clonal AAV insertions were recurrently identified in CCNA2, CCNE1, TERT, TNFSF10, KMT2B and GLI1/INHBE. AAV insertion triggered oncogenic overexpression through multiple mechanisms that differ according to the localisation of the integration site.
CONCLUSION: We provided an integrated analysis of the wild-type AAV infection in the liver with the identification of viral genotypes, molecular forms, helper virus relationship and viral integrations. Clonal AAV insertions were positive selected during HCC development on non-cirrhotic liver challenging the notion of AAV as a non-pathogenic virus. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  carcinogenesis; chronic viral hepatitis; hepatocellular carcinoma; liver; oncogenes

Year:  2019        PMID: 31375600     DOI: 10.1136/gutjnl-2019-318281

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  25 in total

1.  AAV and hepatitis: Cause or coincidence?

Authors:  Ype P de Jong; Roland W Herzog
Journal:  Mol Ther       Date:  2022-08-17       Impact factor: 12.910

2.  AAV integration in human hepatocytes.

Authors:  Dhwanil A Dalwadi; Andrea Calabria; Amita Tiyaboonchai; Jeffrey Posey; Willscott E Naugler; Eugenio Montini; Markus Grompe
Journal:  Mol Ther       Date:  2021-08-28       Impact factor: 12.910

Review 3.  AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer.

Authors:  Helena Costa Verdera; Klaudia Kuranda; Federico Mingozzi
Journal:  Mol Ther       Date:  2020-01-10       Impact factor: 11.454

4.  Development of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B.

Authors:  Harrison C Brown; Christopher B Doering; Roland W Herzog; Chen Ling; David M Markusic; H Trent Spencer; Alok Srivastava; Arun Srivastava
Journal:  Hum Gene Ther       Date:  2020-08-17       Impact factor: 5.695

5.  Liver gene therapy and hepatocellular carcinoma: A complex web.

Authors:  Ype P de Jong; Roland W Herzog
Journal:  Mol Ther       Date:  2021-03-19       Impact factor: 11.454

6.  Liver Injury Increases the Incidence of HCC following AAV Gene Therapy in Mice.

Authors:  Dhwanil A Dalwadi; Laura Torrens; Jordi Abril-Fornaguera; Roser Pinyol; Catherine Willoughby; Jeffrey Posey; Josep M Llovet; Christian Lanciault; David W Russell; Markus Grompe; Willscott E Naugler
Journal:  Mol Ther       Date:  2020-10-22       Impact factor: 11.454

Review 7.  Genomics of Viral Hepatitis-Associated Liver Tumors.

Authors:  Camille Péneau; Jessica Zucman-Rossi; Jean-Charles Nault
Journal:  J Clin Med       Date:  2021-04-22       Impact factor: 4.241

8.  Short regulatory DNA sequences to target brain endothelial cells for gene therapy.

Authors:  Hanna Graßhoff; Helge Müller-Fielitz; Godwin K Dogbevia; Jakob Körbelin; Jacqueline Bannach; Carl Mg Vahldieck; Kristina Kusche-Vihrog; Olaf Jöhren; Oliver J Müller; Ruben Nogueiras; Vincent Prevot; Markus Schwaninger
Journal:  J Cereb Blood Flow Metab       Date:  2021-08-24       Impact factor: 6.960

Review 9.  Novel vectors and approaches for gene therapy in liver diseases.

Authors:  Sheila Maestro; Nicholas D Weber; Nerea Zabaleta; Rafael Aldabe; Gloria Gonzalez-Aseguinolaza
Journal:  JHEP Rep       Date:  2021-04-30

10.  Promoterless, Nuclease-Free Genome Editing Confers a Growth Advantage for Corrected Hepatocytes in Mice With Methylmalonic Acidemia.

Authors:  Randy J Chandler; Leah E Venturoni; Jing Liao; Brandon T Hubbard; Jessica L Schneller; Victoria Hoffmann; Susana Gordo; Shengwen Zang; Chih-Wei Ko; Nelson Chau; Kyle Chiang; Mark A Kay; Adi Barzel; Charles P Venditti
Journal:  Hepatology       Date:  2021-05-21       Impact factor: 17.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.